- Home
- Publications
- Publication Search
- Publication Details
Title
Tofacitinib for the treatment of ulcerative colitis
Authors
Keywords
-
Journal
Expert Review of Clinical Immunology
Volume 14, Issue 11, Pages 881-892
Publisher
Informa UK Limited
Online
2018-10-05
DOI
10.1080/1744666x.2018.1532291
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
- (2018) Kevin L Winthrop et al. INFLAMMATORY BOWEL DISEASES
- DOP025 Tofacitinib for the treatment of ulcerative colitis: analysis of malignancy rates from the OCTAVE clinical programme
- (2018) G R Lichtenstein et al. Journal of Crohns & Colitis
- P516 Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: Results from the OCTAVE clinical trials
- (2018) J Panés et al. Journal of Crohns & Colitis
- DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open
- (2018) B E Sands et al. Journal of Crohns & Colitis
- JAK inhibition in inflammatory bowel disease
- (2017) Pablo Olivera et al. Expert Review of Clinical Immunology
- Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases
- (2017) Clara Abraham et al. GASTROENTEROLOGY
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
- (2017) Marcus Harbord et al. Journal of Crohns & Colitis
- Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies
- (2017) Julian Panés et al. Journal of Crohns & Colitis
- Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy
- (2017) David T. Beattie et al. Journal of Inflammation-London
- A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model
- (2017) Misato Ito et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Ulcerative colitis
- (2017) Ryan Ungaro et al. LANCET
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
- (2016) Megan E. B. Clowse et al. DRUG SAFETY
- Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial
- (2016) William J. Sandborn et al. GASTROENTEROLOGY
- Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis
- (2016) Julian Panés et al. Journal of Crohns & Colitis
- Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies
- (2016) Hendrik Schulze-Koops et al. RHEUMATOLOGY
- Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist
- (2016) Christina Charles-Schoeman et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2016) Mark C. Genovese et al. Arthritis & Rheumatology
- Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
- (2015) Jeffrey R Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes
- (2015) Julián Panés et al. BMC GASTROENTEROLOGY
- Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
- (2015) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
- (2014) J. Wollenhaupt et al. JOURNAL OF RHEUMATOLOGY
- Inflammatory bowel disease: Pathogenesis
- (2014) Yi-Zhen Zhang WORLD JOURNAL OF GASTROENTEROLOGY
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
- (2014) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial
- (2013) M. C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Innate and adaptive immunity in inflammatory bowel disease
- (2013) Alessandra Geremia et al. AUTOIMMUNITY REVIEWS
- Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies
- (2013) Alexandra D. Frolkis et al. GASTROENTEROLOGY
- Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
- (2013) L. Van Rompaey et al. JOURNAL OF IMMUNOLOGY
- Reaction of platinum anticancer drugs and drug derivatives with a copper transporting protein, Atox1
- (2012) Maria E. Palm-Espling et al. BIOCHEMICAL PHARMACOLOGY
- Inborn Errors of Human JAKs and STATs
- (2012) Jean-Laurent Casanova et al. IMMUNITY
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts
- (2011) Fernando Magro et al. INFLAMMATORY BOWEL DISEASES
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
- Intestinal homeostasis and its breakdown in inflammatory bowel disease
- (2011) Kevin J. Maloy et al. NATURE
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
- (2010) Debra M Meyer et al. Journal of Inflammation-London
- Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection
- (2010) Mark E. Flanagan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Treating inflammation with the Janus Kinase inhibitor CP-690,550
- (2010) Lalitha Vijayakrishnan et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment
- (2009) Stanley Cohen et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Anti-inflammatory and pro-inflammatory roles of TGF-β, IL-10, and IL-22 in immunity and autoimmunity
- (2009) Shomyseh Sanjabi et al. CURRENT OPINION IN PHARMACOLOGY
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
- (2009) C H Seow et al. GUT
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- JAK3: A two-faced player in hematological disorders
- (2009) Melanie G. Cornejo et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- High Levels of Proinflammatory Cytokines, but Not Markers of Tissue Injury, in Unaffected Intestinal Areas from Patients with IBD
- (2009) Alberto J. León et al. MEDIATORS OF INFLAMMATION
- Garden of therapeutic delights: new targets in rheumatic diseases
- (2009) Jean M Waldburger et al. ARTHRITIS RESEARCH & THERAPY
- Intracellular signal pathways: Potential for therapies
- (2009) Melissa Mavers et al. Current Rheumatology Reports
- Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials
- (2008) Laurent Peyrin–Biroulet et al. Clinical Gastroenterology and Hepatology
- Therapeutic targeting of Janus kinases
- (2008) Marko Pesu et al. IMMUNOLOGICAL REVIEWS
- Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)
- (2008) Jian-kang Jiang et al. JOURNAL OF MEDICINAL CHEMISTRY
- The role of IL-13 and NK T cells in experimental and human ulcerative colitis
- (2008) I J Fuss et al. Mucosal Immunology
- IL-23 and Th17 cytokines in intestinal homeostasis
- (2008) K J Maloy et al. Mucosal Immunology
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started